Prostate Cancer

Vaccine therapy for men with rising PSA or new bone lesions or enlarging soft tissue mass following treatment with hormone therapy for prostate cancer.
Participants qualify if between 18-85 years of age with a testosterone level less than 50. PSA has to have risen at least two times or there is evidence of a new bone lesion. Participants must have had a previous small pox vaccination.
Exclusions include, but are not limited to: Prior Taxotere treatment, splenectomy or immunodeficiency, inflammatory eye disease, prior Provenge treatment, active skin disease, atopic dermatitis and an egg or gentamycin allergy.

Taxotere chemotherapy with or without an investigational drug for men with rising PSA or new lesions after treatment with hormone therapy for prostate cancer.
Participants must have either 2 consecutive rises in their PSA or 2 or more new bone lesions or increased soft tissue disease. Participants are allowed to continue on their androgen suppression medications.
Exclusions include, but are not limited to: Moderate-severe peripheral neuropathy, brain or central nervous system metastases, previous strontium or samarium, radiation of 25% or more of the bone marrow.

Compares the use of two different doses of Cabazitaxel for men previously treated with Taxotere for hormone resistant prostate cancer.
Participants must have a rising PSA or measurable disease that has progressed. Castration or LHRH angonist/antagonist are allowed. Progression could have occurred during or after treatment. Patients previously treated with Taxtotere are allowed.
Exclusions include, but are not limited to: Moderate-severe peripheral neuropathy, previous mitoxantrone, uncontrolled cardiac conditions or radiotherapy 30% or greater of the bone marrow.

Registry study that collects information about men who have had cryotherapy as a method to control their prostate cancer.
Participants can be 30-80 years of age and must have undergone cryotherapy.
Exclusions include, but are not limited to: Patients who have had a radical prostatectomy, major rectal surgery, significant lower urinary tract anomalies, existing rectal, bladder or urethral fistulas and confirmed distant metastatic disease.

Lakeland Regional Medical Center